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Background.Anemia associated with deficiencies in iron, folic acid, and vitamin B12 are very common after Laparoscopic Roux-
en-Y Gastric Bypass (LRYGB) surgery for morbid obesity. This study was conducted to evaluate the prevalence of anemia after
LRYGB. Patients and Methods. A total of 377 morbid obese patients were included in our study. All patients underwent a LRYGB.
Hematologic parameters were obtained prior to and after surgery on standardized time intervals. Results. Anemia was present in 21
(P = 0.02) patients after surgery. Iron, folic acid, and vitamin B12 deficiencies were diagnosed in 66%, 15%, and 50% of patients,
respectively. In 86% of patients, anemia was accompanied by one of these deficiencies. Conclusion. These results show that anemia
and deficiencies for iron, folic acid deficiency, and vitamin B12 are very common within the first year after LRYGB. We advise a
minimal daily intake of 65mg of iron inmale and 100mg in female patients, 350 µg of vitamin B12, and 400 µg of folic acid. Patients
undergoing LRYGB must be closely monitored for deficiencies pre- and postoperative and supplemented when deficiencies occur.
1. Introduction
Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) is one
of the most commonly performed bariatric procedures to
establish weight loss in morbid obese patients. A sustained
Excess Weight Loss (EWL) of 50–70% is obtained in at least
50% of the patients by combining restrictive and malabsorp-
tion techniques. Sustained weight loss is associated with a
decrease in obesity-related morbidity and mortality and an
increase in quality of life [1–5].
However, due to malabsorption and insuﬃcient intake,
LRYGB patients are prone to develop deficiencies in many
macro- and micronutrients. Most common are deficiencies
in iron, folate, and vitamin B12, all of which can lead to
anemia. Once these deficiencies are present, they can be
diﬃcult to treat by oral vitamin and mineral supplements.
Therefore, patients who undergo RYGB should be evaluated
prior to surgery for deficiencies and treated accordingly. After
surgery, supplementation and close monitoring is warranted
[1, 2, 6–8].
A number of possible risk factors for developing anemia
have been previously researched. Diﬀerences in sex as well
as length of Roux-en-Y limb are described as contributing
factors for the development of certain deficiencies [3].
Also we researched whether the amount of weight loss or
an Adjustable Gastric Band (AGB) prior to the LRYGB
influenced the amount of deficiencies.
Although weight loss eﬀects of RYGB are well established,
the number of studies addressing nutrient deficiencies and
anemia is limited. Furthermore, the studies conducted so
far often include only a small number of patients and are
incongruent in their findings [1, 7]. For this reason we
conducted a prospective study to investigate the prevalence
of anemia and deficiencies in iron, folate, and vitamin B12 in
the first year after LRYGB in our patients.
2. Patients and Methods
Between January 2005 and October 2009 a total of 416
patients underwent an LRYGB in our hospital. All patients
were screened by amultidisciplinary team preoperatively and
met the criteria stated by the NIH Consensus Development
Conference Panel for bariatric surgery [9]. Patients who
were unable to attend our standardized follow-up protocol
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Table 1: Demographics.
Parameter Values (standard deviation)
Number of patients 377
Male 102 (27.1%)
Female 275 (72.9%)
Age 43.4 (18–63)
Age male 46.0 (20–63)
Age female 42.5 (18–62)
Initial weight in kg 137.5 (±22.6)
Male 151.4 (±22.1)
Female 132.4 (±20.6)
Initial BMI in kg/m2 46.8 (±6.3)
Male 47.0 (±6.4)
Female 46.7 (±6.2)
were excluded. Also excluded were patients with laboratory
evaluations that surpassed the six-and 12-month evaluation
with two and three months respectively. Research nurses
assured a minimum of data loss. Hence being part of our
standard intake protocol, all patients were informed about
this study. A total number of 377 (91%) patients scheduled
for LRYGB were included in this study. We included 102
(27%) male patients and 275 (73%) female patients with a
mean age of 43 (18–63) years. Medium follow-up time was
13.7 months. Demographics are shown in Table 1.
In our clinic, the proximal gastric volume is reduced by
stapling of a 30 cc proximal gastric pouch and connecting a
100 or 150 cm roux-en-y limb as an enteroenterostomy to the
jejunum 40 cm from the ligament of Treitz. Limb length was
based on the patients BMI between 2005 and 2007. Patients
with a BMI > 40 kg/m2 received a 100 cm limb. Patients with
a BMI > 50 kg/m2 or a failing gastric band were treated with
a 150 cm limb. Since 2007, all patients received a 150 cm
limb. After surgery, patients were followed up at 1, 3, 6, and
12 months. Standard laboratory evaluation was performed
preoperatively consisting of a complete blood count, a mean
cell volume (MCV), and kidney function. After six and
twelve months, laboratory evaluation was repeated along
with plasma levels for iron, total iron binding capacity
(TIBC), serum folate levels, and serum vitamin B12 levels.
Patients were instructed to take a standard multivitamin
tablet three times daily. These tablets contained at least 7mg
of iron, 100 µg of folic acid, and 0.5 µg of vitamin B12 per
tablet. Our standard postoperative medication consisted of a
CaD 1000/880 sachet to prevent bone loss, Omeprazol 40mg
once daily to prevent ulceration of the staple line and the
remaining stomach, and 5700U of Fraxiparine once daily for
six weeks postoperative for preventing thrombosis. During
each visit patients were asked about their medication use so
as to estimate their compliance to our described medication.
Anemia was defined as a hemoglobin (Hb) level
<8.4mmol/L in men and <7.4mmol/L in women. MCV
was defined normal between 80 and 100 fL. Iron deficiency
was defined by serum levels <9.0 µmol/L. Total iron binding
capacity was defined as high when >80%. Folate deficiency
Table 2: Laboratory outcomes before RYGB.
Level Number of patients (%)
Hb
Low 27 (7,9%) of which 9 microcytic
Normal
350 (92,9%) of which 13 microcytic
and 5 macrocytic
MCV
Microcytic 22 (5,8%)
Normocytic 350 (92,9%)
Macrocytic 5 (1,3%)
was defined by serum levels <9.0 nmol/L. Cobalamin defi-
ciency was defined by serum levels <150 pmol/L. Once a
deficiency was identified treatment was started accordingly.
3. Statistics
Data were prospectively collected and evaluated using
SPSS16 for Windows. All data are reported as mean ±
standard error of the mean. To evaluate the results between
groups, logistic regression was used. Evaluation of laboratory
results was performed using a paired T-tests. P < 0.05 was
considered significant.
Patients who were anemic preoperative were excluded
for the 12 months evaluation (Table 3 N = 350) and were
evaluated separately (Table 4 N = 27).
4. Results
Before surgery, anemia was present in 27 (7%) patients. After
twelve months, 66 (19%) patients had developed anemia de
novo, of which 19 (29%) were microcytic. In these patients
mean Hb levels dropped from 8.2mmol/L to 7.1mmol/L
(P < 0.001). Total prevalence of anemia diagnosed in
the first year, including preoperative anemic patients, was
25%. Preoperative laboratory results are shown in Table 2.
A total of 93 patients were diagnosed with or developed
anemia during the first postoperative year. The percentage
of deficiencies in patients with anemia are separately shown
in Table 3. The percentage of patients with iron, folic acid,
and vitamin B12 deficiencies were 66%, 15%, and 50%,
respectively. In 86% of patients, anemia was accompanied by
one of these deficiencies.
Analysis of deficiencies in all patients is shown in Table 4.
Iron deficiency after one year was identified in 33% of
patients and in 61% of our patients with anemia de novo
(P < 0.001). The percentage of patients with folic acid
and vitamin B12 deficiency were 14% and 40%, respectively.
Three patients developed macrocytic red blood cells, and
in two cases a vitamin B12 deficiency was found. Of all
patients, 239 (63%) were diagnosed with at least one of the
deficiencies mentioned above.
Risk factor analysis is presented in Table 5. Many diﬀer-
ences between male and female patients were found in the
prevalence of iron (38% versus 17%, P = 0.02), and vitamin
B12 (42% versus 21% P = 0.03) deficiencies. However,
the percentage for developing anemia in these groups was
similar, 20%. Male patients had a 45% risk of being
diagnosed with an iron, folic acid, or vitamin B12 deficiency,
whereas female patients had a 68% risk (P = 0.004).
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Table 3: 12 Month evaluation of anemic patients.
Anemia preoperative (%) Anemia de novo (%) Anemia total (%)
N patients 27 (7.1%) 66 (18.8%) 93 (24.7%)
MCV
Micro 10 (37.0%) 19 (18.8%) 29 (31.2%)
Macro 0 (0%) 1 (1.5%) 1 (1.0%)
High TIBC 4 (14.8%) 10 (15.2%) 14 (15.1%)
Iron deficiency 21 (77.8%) 40 (60.6%) 61 (65.6%)
Folic acid deficiency 4 (14.8%) 11 (16.7%) 15 (16.1%)
Vitamin B12 deficiency 14 (52%) 33 (50.0%) 47 (50.4%)
Total deficiency 23 (85.2%) 57 (86.4%) 80 (86.0%)
In the anemia preoperative column, laboratory results are shown of patients with anemia preoperative. In the anemia de novo column, patients with anemia
preoperative were excluded. In the anemia total column, all patients are evaluated.
Table 4: 12 Month evaluation of all RYGB patients.
Month
6 (%)
Month
12 (%)
Total
(%)
Anemia
50
(13.3%)
71
(18.8%)
93
(24,7%)
MCV
Micro
24
(6.4%)
20
(5.3%)
34
(9.0%)
Macro
4
(1.1%)
6
(1.6%)
8
(2.1%)
Elevated TYBC
17
(4.5%)
26
(6.9%)
32
(8.5%)
Iron deficiency
79
(21%)
78
(20.7%)
124
(32.9%)
Folic acid deficiency
34
(9.0%)
25
(6.6%)
51
(13.6%)
Vitamin B12 deficiency
89
(23.6%)
71
(18.8%)
152
(40.2%)
Total deficiency
175
(46.4%)
150
(39.8%)
239
(63.4%)
T6 = laboratory findings (%) at 6 months, T12 = laboratory findings (%) at
12 months. N = 377.
Further analysis was done to investigate the role of Roux-
en-Y limb length in the onset of deficiencies. No significant
diﬀerences were found. A number of patients were treated
with a AGB prior to RYGB surgery. A significant diﬀerence
(24% versus 39% P = 0.03) in vitamin B12 deficiencies
between these groups was found. Surprisingly the percent-
ages for anemia, folic acid, and vitamin B12 deficiencies were
lower in the group who had a previous AGB placement.
Patients who lost over 70% of their excess weight in one
year were less likely to develop anemia and deficiencies for
folic acid and vitamin B12 compared to patients below 70%
EWL.
5. Discussion
Bypassing the duodenum and proximal jejunum leads to
a decrease in absorption surface for specific nutrients and
causes a reduction in the absorptive capacity. After an LRYGB
the most common reported are iron and vitamin B12 defi-
ciencies. Deficiencies in these micronutrients are well known
causes for anemia [1, 7, 10]. Published reports on metabolic
deficiencies after RYGB with diﬀerent follow-up periods
found anemia varying from 18 to 35%. Iron deficiency was
reported in 20–49% in these studies. Folate deficiency was
found in 0–18% of the cases. Vitamin B12 deficiency varied
from 26 to 70% [11–16]. Although a relative short followup
of only one year, we found high percentages in folic acid and
vitamin B12 deficiencies, of 19 and 36%, respectively.
Iron deficiency after RYGB is due to a combination
of factors and is the main cause for developing anemia
after an RYGB [17, 18]. Absorption is dependent on the
pH of the stomach. Acid reduces iron from a ferric state
(Fe3+) to a ferrous state (Fe2+), which is readily absorbed
in the duodenum and proximal jejunum. Due to the RYGB
configuration, iron passes through the small gastric pouch
without being reduced to the ferrous state. This eﬀect is
further enhanced by the prescribed protonpump inhibitors
and calcium. After ingestion, iron bypasses the absorptive
surface of the duodenum and jejunum. Iron intake is further
reduced by the frequently found intolerance for red meat
[10, 19]. A normal individual requires 1-2mg of iron daily
as a minimum. Especially premenopausal female are prone
for developing iron deficiency [3, 11, 12, 17].
Preoperative 8% of our patients were anemic and another
5% had micro- or macrocytic red blood cells. These findings
are most likely due to an unvaried intake of macro- and
micronutrients by these patient [10, 19]. This shows that
testing patients for anemia and deficiencies in iron, folate,
and vitamin B12 preoperative is needed to achieve the best
medical care for the bariatric patient. Patients should be
treated for their deficiencies preoperative to prevent symp-
tomatic anemia, deficiencies, and possible complications
during and after surgery. In case of preoperative deficiencies,
patients in our clinic are treated with high doses of iron
(200mg a day), vitamin B12 injections (3000 µg every week),
and folic acid (2mg a day). These amounts are used until an
adequate serum level is reached.
In our study, 56% of the patients who developed anemia
de novo also had an iron deficiency and 42% had microcytic
red blood cells. Of the patients who did not develop anemia
within the first year, another 32% appeared to be iron
deficient and may develop anemia in the near future if not
treated. In our study, we prescribed all patients Omeprazol
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tablets and CaD 1000/880 sachets. This may increase the
percentage of iron deficiencies because Omeprazol reduces
acid secretion and subsequent iron absorption. Calcium can,
when taken around the same time as iron, decrease the
uptake of iron up to 60% [20]. The amount of iron (21mg
daily) supplemented did not prevent iron deficiency in a
large number of patients. Most recent recommendations
in the literature advise a daily intake of 40 to 65mg of
elemental iron per day for male and 100mg per day for
female patients. Vitamin C added to this regimen may also
improve absorption [15, 18, 19].
Folic acid is present in food as polyglutamates and must
be hydrolyzed to monoglutamates by the intestinal brush
border. Folic acid absorption predominantly takes place in
the upper third of the small intestine but can be absorbed
throughout the small intestine [18]. Absorption is pH
dependent and therefore partially facilitated by hydrochloric
acid. Additionally, vitamin B12 acts as a coenzyme in
converting folic acid to an absorbable form thus a vitamin
B12 deficiency may result in a folate deficiency [20, 21].
Due to the low acid production of the proximal pouch
and the bypassing of the upper third of the small intestine,
RYGB patients are at risk for developing folic acid deficiency
[21, 22]. Enterohepatic recirculation is an important factor in
preserving the body pool of folate [19]. Another contributing
factor for developing a folic acid deficiency may be due to
the malabsorption and the short bowel in RYGB patients.
Despite these apparent mechanisms for folate deficiency,
decreased dietary intake of folic acid seems the dominant
cause. Since folic acid reserves are low with an average of
10mg, a daily requirement of 50 µg, and a deficit absorption,
deficiency can occur rapidly [20, 23].
In this study, 19% of the patients were diagnosed
with folic acid deficiency. A number of studies found a
substantial decrease in folic acid deficiencies over the years.
An explanation for this decrease may be that folic acid
absorption in the distal small intestine compensates for the
reduced absorption capacity. Another mechanism might be
based on bacteria in the upper small bowel who produce
more folic acid over time [24, 25].
The 300 µg of folic acid prescribed per day appears
insuﬃcient to avoid a deficiency in the first year. A suﬃcient
quantity of folic acid should be at least 400 µg per day, while
most authors prescribe 1mg of folic acid a day [12, 20]. Folic
acid deficiency may be of great concern in female patients
who want to became pregnant in the near future after RYGB.
Although uncommon, reports of neural tube defects have
been reported in infants after RYGB surgery [12, 26].Woman
of reproductive age should be monitored closely, bearing in
mind that one of the reasons for undergoing an RYGB is
decreased fertility due to morbid obesity.
Vitamin B12 in food is bound to proteins and first needs
to be released by pepsin and hydrochloric acid before it
can be bound by intrinsic factor (IF). When the released
vitamin B12 in a normal individual enters the duodenum, it
is bound to IF released from the parietal cells of the stomach
facilitated by pepsin and pancreatic enzymes. In this state, the
bound vitamin B12 is eventually absorbed in the terminal
ileum. After RYGB, vitamin B12 cannot be released from
the food and is hardly bound to IF due to the bypassing of
the stomach and duodenum and the reduced amount of IF
released [27, 28]. The frequently found intolerance for red
meat and milk might also play a role, as these products are
rich in vitamin B12. In healthy subjects, a daily minimal dose
of 2 µg vitamin B12 per day is needed. A normal individual
has a vitamin B12 reserve of 2000 µg, which should last for a
minimum of two years [19, 24, 29, 30].
LRYGB patients appear to have much lower vitamin
B12 reserves than healthy individuals, probably due to
inadequate dietary intake preoperatively. The multivitamins
prescribed contains 1,5 µg of vitamin B12 per day. Several
studies have shown that a 300–500 µg dose of vitamin B12
is suﬃcient. Others recommend sublingual administration
or intramuscular injections of 1000–3000 µg every month to
every six months and report similar outcomes for resulting
vitamin B12 levels [12, 15, 28, 31–33]. In the case of vitamin
B12, the prescribed Omeprazol may also decrease absorption
[20]. Although none of our patients became symptomatic for
B12 deficiency, there have been reports of patients developing
Wernicke’s encephalopathy and megaloblastic anemia years
after RYGB [34–39].
The risk factors studied for developing metabolic defi-
ciencies showed a number of interesting results. A number of
studies reported a diﬀerence for developing anemia and iron
deficiency between male and female patients who had under-
went RYGB [11, 12, 17]. Anemia and iron deficiency are
thought to be higher among woman, because premenopausal
women lose iron during menstruation every month and
often have no iron reserves [11, 12, 17, 40]. This study did
not find a significant diﬀerence in the prevalence for anemia
between the sexes. In fact, the prevalence was identical at
20%. This shows that the first year after LRYGB the risk for
developing anemia is equal betweenmale and female patients
after RYGB surgery for morbid obesity. We did, however,
find significant higher percentages for iron and vitamin B12
deficiencies in female patients. From these data one could
conclude that on the long run female patients may have a
higher risk for developing anemia. The diﬀerence in iron
deficiencies between males and females can be explained by
the average lower iron reserves of females, combined with the
loss of iron during menstruation. The diﬀerence in vitamin
B12 might be explained by the average lower daily intake of
vitamin B12 by female patients compared to male patients
(4 µg versus 7 µg). Of all the patients who developed anemia,
71% were female. This greater number is due to the fact that
a greater number of patients undergoing RYGB were female.
The diﬀerent lengths of the Roux-en-Y limb did not show
any significant outcomes. Although the 150 cm limb group
showed a 6% higher prevalence for anemia and lower values
for folic acid and vitamin B12 deficiencies, these values were
not significant. Brolin et al. also found lower deficiency rates
for vitamin B12 with an increase of the Roux-en-Y limb
length.
Patients with an AGB prior to an RYGB had a lower
prevalence’s for anemia, folic acid deficiency, and even a
significant lower risk of vitamin B12 deficiency (P = 0.03).
These patients were already used to taking multivitamin
tablets during the period they had an AGB. Thus resulting
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in higher baseline values and a better compliance (92
versus 76%). These diﬀerences may explain the unexpected
diﬀerences in deficiencies found.
We expected the group who lost >70% of their EWL to
have higher prevalence’s of deficiencies due to a decreased
intake of macro- and micronutrients. The prevalence of iron
deficiency was as expected higher in the >70% group, but all
the other prevalence’s were lower in this group. The diﬀer-
ence in vitamin B12 deficiency was almost significant (P =
0.07) and might be explained by the release of vitamin B12
from the shrinking liver and fatty tissue. This mechanismwill
only protect these patients during the rapid weight loss. After
this period, the micronutrient stores will be depleted.
6. Conclusion
Our results show that anemia and deficiencies for iron, folic
acid, and vitamin B12 are very common the first year after
LRYGB. Women are at risk for developing iron deficiency
and vitamin B12 deficiency and have a greater overall risk for
developing one of the deficiencies researched. Our standard
policy for supplementation of multivitamin tablets after
LRYGB failed to prevent deficiencies. We advise a minimal
daily intake of 65mg of iron in male and 100mg in female
patients, 350 µg of Vitamin B12 and 400 µg of folic acid.
With this paper we want to create awareness for screening
RYGB patients for deficiencies and correcting these within
the first year. Furthermore, supplementing these patients
with multivitamins should only be regarded as a base upon
which a patient-specific regimen for micronutrients should
be built.
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